Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research focused on Breast cancer and Stage (stratigraphy), with related work in Oncology, China, Trastuzumab. Notable publications include 'Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022', 'Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020', and 'Effect of an Artificial Intelligence Clinical Decision Support System on Treatment Decisions for Complex Breast Cancer'.
Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2
Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus
Predictors of COVID-19 severity in autoimmune disease patients: A retrospective study during full epidemic decontrol in China
Abstract PO2-04-02: Trends in Disparities and Transitions of target therapy in Patients With ERBB2 Positive Early Breast Cancer in China and the US, 2011 to 2021
Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021
A comparison between clinical decision support system and clinicians in breast cancer
Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China
Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China
601P Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Disparities and Transitions of Early Breast Cancer in China and USA Over the Decade
A comparison between a clinical decision support system and clinicians with guidelines in breast cancer.
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)
A Comparison Between CSCO AI and Clinicians in Breast Cancer: A Double-Blind, Controlled Phase III Trial
A Comparison between Clinical Decision Support System and Clinicians in Breast Cancer
Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast Cancer
Chinese expert consensus on coronavirus disease 2019 vaccination for breast cancer patients
Introduction to the special issue: Management Science in the Fight Against Covid-19
More than 14 years’ progress free survival of neratinib monotherapy for human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer: a case report
Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020
Effect of an Artificial Intelligence Clinical Decision Support System on Treatment Decisions for Complex Breast Cancer
Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China
Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
Neoadjuvant chemotherapy versus surgery as the initial option for T3 breast cancer (>5 cm): real-world evidence from the Chinese Society of Clinical Oncology Breast Cancer database
Neoadjuvant chemotherapy or surgery: which is the optimal initial option for T3 breast cancer (> 5 cm)——a real world research from Chinese society of clinical oncology breast cancer database
Artificial Intelligence Treatment Decision Support For Complex Breast Cancer Among Oncologists With Varying Expertise
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China
[Current status of research on target delineation of partial breast external irradiation after breast-preserving surgery of early breast cancer patients].
PubMed 2013cited by 0position: last